Loading...
•
Mar 31, 2021
Amneal Q1 2021 Earnings Report
Amneal reported solid first quarter results, continuing its positive momentum as it consistently executed against its Amneal 2.0 strategic vision.
Key Takeaways
Amneal Pharmaceuticals reported a net revenue of $493 million for Q1 2021, a slight decrease of 1% compared to the previous year. The company's GAAP net income was $7 million, with a diluted income per share of $0.04. Adjusted EBITDA stood at $126 million, and adjusted diluted EPS was $0.20. The company is maintaining its full year 2021 financial outlook.
Q1 2021 net revenue was $493 million.
GAAP net income was $7 million, resulting in diluted income per share of $0.04.
Adjusted EBITDA was $126 million and adjusted diluted EPS was $0.20.
Amneal is maintaining its 2021 full year financial outlook.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Specialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal is maintaining its previously provided guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income